Atrial Fibrillation & SPAF |
||||||||||||
| CVrg’s extensive coverage of Atrial Fibrillation and Stroke Prevention in AF includes antiarrhythmic agents for cardioversion and treatment of AF, as well as factor Xa and direct thrombin inhibitors, vitamin K antagonists, anticoagulant antidotes, and other agents in development for stroke prevention. | ||||||||||||
 Jennifer Lilla, Ph.D.Therapy Area Director, AF/SPAF Jennifer received her Ph.D. in Biomedical Sciences from the University of California, San Francisco and postdoctoral training at Stanford University’s School of Medicine before joining CVrg. In addition to her solid technical foundation, she brings strong analytic abilities and strategic planning experience as well as communication, writing and presentation skills to her leadership role in our thrombosis area. |
Atrial Fibrillation & SPAF, 2018–2027 is a cutting-edge detailed market research report with unmatched scope, depth, and accuracy. This best-in-class resource provides a highly granular assessment of new product development, emerging trends, unmet needs, epidemiology, current treatment and market landscapes. KOL comments, SWOTs, clinical trial tracking, estimations of launch dates and target patient populations are included for products ≥Ph 2 along with regional coverage of USA, EU5, and Japan. Fresh new data and analytical observations gained throughout the year in AF/SPAF from CVrg Sentinel, Conference, Insights and Advisory research are also included. |
CVrg continuously monitors how new scientific, clinical, regulatory and market developments are changing the commercial potential of AF/SPAF assets. This monthly delivery informs clients about what is happening in the marketplace and how it might affect their products.
CVrg keeps abreast of cutting edge clinical data by attending cardio-metabolic congresses such as ACC, ESC and AHA. Our experts carefully analyze the new data presented and deliver incisive, presentation-style reports informing subscriber organizations about what’s new, what’s important, and why
CVrg experts conduct primary research with KOLs in several disease areas, using their critical eyes to evaluate emerging trends, pipeline products and implications for the field. Clients may review and add to our “omnibus” discussion guides and receive detailed reports and presentations focused on answering the most pressing issues they face today. *Additional fees may apply.
CVrg is uniquely positioned to deliver quick, thorough and reliable answers to non-proprietary questions in AF/SPAF drug markets. We are immediately equipped with comprehensive data and put our best methodologies and efforts behind each inquiry so clients receive the most accurate insight possible within a given timeframe. |
||||||||||
|
Pricing & Information: Call: 541-977-1516 e-mail: blackwelder@cv-rg.com
|
||||||||||||
